Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07307326 · ClinicalTrials.gov registry record · NA

Biomarker Feedback Intervention

A NA study, sponsored by Penn State University.

Not yet
Registry status
NA
Development phase
150
Enrollment target

NCT07307326: Clinical Trial NA study, sponsored by Penn State University.

NCT07307326 is a NA study that has not yet begun recruiting, run by Penn State University. The registered enrollment target is 150 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07307326, a NA study, has not yet begun recruiting, sponsored by Penn State University.

NOT YET RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target

Study Summary

The goal of the study is to examine alcohol use behaviors of young adults through the use of testing the feasibility of adding an innovative brief personalized alcohol biomarker feedback component (TAC feedback) to an existing efficacious personalized feedback intervention, eCHECKUP TO GO (eCTG), and how (if at all) the intervention impacts drinking behaviors in high-risk college students. The study will conduct a feasibility assessment of the TAC feedback component, and will also assess the effects of the eCTG + TAC at 6-months post-baseline relative to an eCTG only group.

Primary Outcome

TAC rise rate will be collected via the BACtrack Skyn wrist sensor, which measures transdermal alcohol concentration (TAC) in micrograms of ethanol per liter of air every 20 seconds to obtain biomarkers - rise rate is a TAC increase.

Interventions

  • BEHAVIORAL eCHECKUP TO GO (eCTG)
  • BEHAVIORAL eCHECKUPTOGO + brief personalized alcohol biomarker feedback intervention (eCTG + TAC)

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-10-15
Est. Completion 2027-12-15
Phase NA
Penn State University

219 total trials

What is known before NCT07307326 opens enrollment

NCT07307326 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 2 interventions - of which eCHECKUP TO GO (eCTG) is the first listed.

NCT07307326 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07307326 about?

NCT07307326 is a clinical study titled "Biomarker Feedback Intervention". The goal of the study is to examine alcohol use behaviors of young adults through the use of testing the feasibility of adding an innovative brief personalized alcohol biomarker feedback component (TAC feedback) to an existing efficacious personalized feedback intervention, eCHECKUP TO GO (eCTG), an...

What is the current status of trial NCT07307326?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2026-10-15. Estimated completion is 2027-12-15.

What interventions are being tested in trial NCT07307326?

The interventions under investigation include: eCHECKUP TO GO (eCTG) (BEHAVIORAL), eCHECKUPTOGO + brief personalized alcohol biomarker feedback intervention (eCTG + TAC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT07307326?

This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07307326's enrollment target sits among peer trials

150 661st of 2000 higher than 1,299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07307326, the US trial registry maintained by the National Library of Medicine. NCT07307326 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.